<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2(6)</volume><submitter>Guo Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>There are limited data on mobile health detection of prevalent atrial fibrillation (AF) and its related risk factors over time.&lt;h4>Objectives&lt;/h4>This study aimed to report the trends on prevalent AF detection over time and risk factors, with a consumer-led photoplethysmography screening approach.&lt;h4>Methods&lt;/h4>3,499,461 subjects aged over 18 years, who use smart devices (Huawei Technologies Co.) were enrolled between October 26, 2018, and December 1, 2021.&lt;h4>Results&lt;/h4>Among 2,852,217 subjects for AF screening, 12,244 subjects (0.43%; 83.2% male, mean age 57 ± 15 years) detected AF episodes. When compared with 2018, the risk (adjusted HRs, 95% CI) for monitored prevalent AF increased significantly for subjects when monitoring started in 2020 (adjusted HR: 1.34; 95% CI: 1.27-1.40; &lt;i>P&lt;/i> &lt; .001) or in 2021 (adjusted HR: 1.67; 95% CI: 1.59-1.76; &lt;i>P&lt;/i> &lt; 0.001). Of the 961,931 subjects who screening for both AF and OSA, 18,032 (1.9%, 97.8% male, mean age 44 ±17 years) were identified as high risk for OSA, which resulted in a 1.5-fold increase (95% CI: 1.30-fold to 1.75-fold) in the prevalent AF. A total of 5,227 (53.3%, 5,227/9,797) subjects were effectively followed up, from which 4,903 (93.8%, 4,903/5,227) subjects were confirmed with the diagnosis of AF, by the mAFA Telecare Team health providers.&lt;h4>Conclusions&lt;/h4>Photoplethysmography-based smart devices can facilitate screening for AF with >93% confirmation of detected AF episodes even for the low-risk general population, highlighting the increased risk for detecting prevalent AF and the need for modification of OSA that increase AF susceptibility. (Mobile Health [mHealth] Technology for Improved Screening, Patient Involvement and Optimizing Integrated Care in Atrial Fibrillation [mAFA (mAF-App) II study]; ChiCTR-OOC-17014138).</pubmed_abstract><journal>JACC. Asia</journal><pagination>737-746</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9700030</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort.</pubmed_title><pmcid>PMC9700030</pmcid><pubmed_authors>mAF-App II Trial investigators</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Lip GYH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Consumer-Led Screening for Atrial Fibrillation: A Report From the mAFA-II Trial Long-Term Extension Cohort.</name><description>&lt;h4>Background&lt;/h4>There are limited data on mobile health detection of prevalent atrial fibrillation (AF) and its related risk factors over time.&lt;h4>Objectives&lt;/h4>This study aimed to report the trends on prevalent AF detection over time and risk factors, with a consumer-led photoplethysmography screening approach.&lt;h4>Methods&lt;/h4>3,499,461 subjects aged over 18 years, who use smart devices (Huawei Technologies Co.) were enrolled between October 26, 2018, and December 1, 2021.&lt;h4>Results&lt;/h4>Among 2,852,217 subjects for AF screening, 12,244 subjects (0.43%; 83.2% male, mean age 57 ± 15 years) detected AF episodes. When compared with 2018, the risk (adjusted HRs, 95% CI) for monitored prevalent AF increased significantly for subjects when monitoring started in 2020 (adjusted HR: 1.34; 95% CI: 1.27-1.40; &lt;i>P&lt;/i> &lt; .001) or in 2021 (adjusted HR: 1.67; 95% CI: 1.59-1.76; &lt;i>P&lt;/i> &lt; 0.001). Of the 961,931 subjects who screening for both AF and OSA, 18,032 (1.9%, 97.8% male, mean age 44 ±17 years) were identified as high risk for OSA, which resulted in a 1.5-fold increase (95% CI: 1.30-fold to 1.75-fold) in the prevalent AF. A total of 5,227 (53.3%, 5,227/9,797) subjects were effectively followed up, from which 4,903 (93.8%, 4,903/5,227) subjects were confirmed with the diagnosis of AF, by the mAFA Telecare Team health providers.&lt;h4>Conclusions&lt;/h4>Photoplethysmography-based smart devices can facilitate screening for AF with >93% confirmation of detected AF episodes even for the low-risk general population, highlighting the increased risk for detecting prevalent AF and the need for modification of OSA that increase AF susceptibility. (Mobile Health [mHealth] Technology for Improved Screening, Patient Involvement and Optimizing Integrated Care in Atrial Fibrillation [mAFA (mAF-App) II study]; ChiCTR-OOC-17014138).</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-19T21:42:52.468Z</modification><creation>2025-04-19T21:42:52.468Z</creation></dates><accession>S-EPMC9700030</accession><cross_references><pubmed>36444321</pubmed><doi>10.1016/j.jacasi.2022.07.006</doi></cross_references></HashMap>